Diacerein and Myo-inositol Alleviate Letrozole-induced PCOS Via Modulation of HMGB1, SIRT1, and NF-kB: A Comparative Study

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2024 Oct 21

PMID 39432066

Authors

Suzan A Khodir

Eman Sweed

Shaimaa Mohamed Motawea

Marwa A Al-Gholam

Sherin Sobhy Elnaidany

Mohamed Zakaria Sayer Dayer

Omnia Ameen

Affiliations

Soon will be listed here.

Abstract

Polycystic ovary syndrome (PCOS) is the most prevalent cause of anovulatory infertility in women. Myo-inositol supplementation has displayed effectiveness in curing PCOS patients. Diacerein, an anti-inflammatory medication, has not been extensively studied in the context of reproductive disorders. This study aimed to compare the role of myo-inositol and diacerein in PCOS and the probable mechanisms mediating their actions. Forty adult female rats were divided equally into the following: control, PCOS, PCOS+Myo-inositol, and PCOS+Diacerein groups. Rats were subjected to arterial blood pressure (ABP), electromyography (EMG), and uterine reactivity measurements. Blood samples were collected for measuring hormonal assays, glycemic state, lipid profile, oxidative stress, and inflammatory markers. Ovaries and uteri were extracted for histological examination, including hematoxylin and eosin staining, Masson's trichrome staining, immunohistochemistry, and rt-PCR analysis of ovarian tissues. PCOS was associated with significant increases in ABP, uterine frequency and amplitude of contraction, luteinizing hormone, testosterone, lipid, glycemic and inflammatory markers, malondialdehyde, high-mobility group box 1 (HMGB1), nuclear factor kappa (NF-kB), ovarian fibrosis, and endometrial thickening. In contrast, there was a significant reduction in follicular stimulating hormone, reduced glutathione, and Sirtuin 1 (SIRT1) when compared with control group. Both myo-inositol and diacerein counteract PCOS changes; but diacerein's effects were superior to myo-inositol's for all parameters, except for lipid and glycemic markers. Diacerein possessed anti-inflammatory properties and showed significant efficacy in mitigating the endocrinal, metabolic, and ovarian structural alterations linked to PCOS. Its beneficial actions likely stem from reducing oxidative stress, dyslipidemia, and hyperglycemia, potentially through the modulation of HMGB1, SIRT1, and NF-kB pathways.

Citing Articles

SRC involves in lysosomal function and regulates ferroptosis in polycystic ovary syndrome.

Wang T, Chen X, Li C J Ovarian Res. 2025; 18(1):42.

PMID: 40045372 PMC: 11881414. DOI: 10.1186/s13048-025-01637-y.

References

Abdel-Gaber S, Mohammed R, Refaie M . Mechanism mediating the protective effect of diacerein in ischemia-reperfusion-induced testicular injury in rats. Life Sci. 2018; 209:57-62. DOI: 10.1016/j.lfs.2018.07.060. View

Al-Kuraishy H, Al-Gareeb A, Alkazmi L, Habotta O, El-Saber Batiha G . High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons. Inflammopharmacology. 2022; 30(3):811-820. PMC: 9040700. DOI: 10.1007/s10787-022-00988-y. View

Almezgagi M, Zhang Y, Hezam K, Shamsan E, Gamah M, Al-Shaebi F . Diacerein: Recent insight into pharmacological activities and molecular pathways. Biomed Pharmacother. 2020; 131:110594. DOI: 10.1016/j.biopha.2020.110594. View

Antonowski T, Osowski A, Lahuta L, Gorecki R, Rynkiewicz A, Wojtkiewicz J . Health-Promoting Properties of Selected Cyclitols for Metabolic Syndrome and Diabetes. Nutrients. 2019; 11(10). PMC: 6835238. DOI: 10.3390/nu11102314. View

Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham N . Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc Diabetol. 2020; 19(1):7. PMC: 6953156. DOI: 10.1186/s12933-019-0980-4. View

Balasubramanian A, Pachiappan S, Mohan S, Adhikesavan H, Karuppasamy I, Ramalingam K . Therapeutic exploration of polyherbal formulation against letrozole induced PCOS rats: A mechanistic approach. Heliyon. 2023; 9(5):e15488. PMC: 10173408. DOI: 10.1016/j.heliyon.2023.e15488. View

Barakat N, Barakat L, Zakaria M, Khirallah S . Diacerein ameliorates kidney injury induced by cisplatin in rats by activation of Nrf2/Ho-1 pathway and Bax down-regulation. Saudi J Biol Sci. 2021; 28(12):7219-7226. PMC: 8626266. DOI: 10.1016/j.sjbs.2021.08.025. View

Beresniak A, Russo M, Forte G, Lagana A, Oliva M, Aragona C . A Markov-model simulation of IVF programs for PCOS patients indicates that coupling myo-Inositol with rFSH is cost-effective for the Italian Health System. Sci Rep. 2023; 13(1):17789. PMC: 10584971. DOI: 10.1038/s41598-023-44055-0. View

Camili F, Akis M, Adali E, Hismiogullari A, Islimye Taskin M, Guney G . Oncostatin M Is Related to Polycystic Ovary Syndrome-Case Control Study. Biomedicines. 2024; 12(2). PMC: 10886802. DOI: 10.3390/biomedicines12020355. View

10.

Chatree S, Thongmaen N, Tantivejkul K, Sitticharoon C, Vucenik I . Role of Inositols and Inositol Phosphates in Energy Metabolism. Molecules. 2020; 25(21). PMC: 7663797. DOI: 10.3390/molecules25215079. View

11.

Cirillo F, Catellani C, Lazzeroni P, Sartori C, Tridenti G, Vezzani C . HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA). Gynecol Endocrinol. 2020; 36(7):588-593. DOI: 10.1080/09513590.2020.1725967. View

12.

Colazingari S, Treglia M, Najjar R, Bevilacqua A . The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013; 288(6):1405-11. DOI: 10.1007/s00404-013-2855-3. View

13.

Deng T, Du J, Yin Y, Cao B, Wang Z, Zhang Z . Rhein for treating diabetes mellitus: A pharmacological and mechanistic overview. Front Pharmacol. 2023; 13:1106260. PMC: 9868719. DOI: 10.3389/fphar.2022.1106260. View

14.

Deswal R, Narwal V, Dang A, Pundir C . The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. J Hum Reprod Sci. 2021; 13(4):261-271. PMC: 7879843. DOI: 10.4103/jhrs.JHRS_95_18. View

15.

DiNicolantonio J, OKeefe J . Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart. 2022; 9(1). PMC: 8896029. DOI: 10.1136/openhrt-2022-001989. View

16.

Fouad A, Abdel-Aziz A, Hamouda A . Diacerein Downregulates NLRP3/Caspase-1/IL-1β and IL-6/STAT3 Pathways of Inflammation and Apoptosis in a Rat Model of Cadmium Testicular Toxicity. Biol Trace Elem Res. 2019; 195(2):499-505. DOI: 10.1007/s12011-019-01865-6. View

17.

Gao Y, Zou Y, Wu G, Zheng L . Oxidative stress and mitochondrial dysfunction of granulosa cells in polycystic ovarian syndrome. Front Med (Lausanne). 2023; 10:1193749. PMC: 10336225. DOI: 10.3389/fmed.2023.1193749. View

18.

Celia Teixeira Gomes R, Maioral G, Verna C, Patriarca M, Nader H, Simoes R . Hyperprolactinemia changes the sulfated glycosaminoglycan amount on the murine uterus during the estrous cycle. Fertil Steril. 2013; 100(5):1419-27. DOI: 10.1016/j.fertnstert.2013.06.048. View

19.

Gudovic A, Bukumiric Z, Milincic M, Pupovac M, Andjic M, Ivanovic K . The Comparative Effects of Myo-Inositol and Metformin Therapy on the Clinical and Biochemical Parameters of Women of Normal Weight Suffering from Polycystic Ovary Syndrome. Biomedicines. 2024; 12(2). PMC: 10886614. DOI: 10.3390/biomedicines12020349. View

20.

Guney G, Islimye Taskin M, Sener N, Tolu E, Dodurga Y, Elmas L . The role of ERK-1 and ERK-2 gene polymorphisms in PCOS pathogenesis. Reprod Biol Endocrinol. 2022; 20(1):95. PMC: 9241270. DOI: 10.1186/s12958-022-00967-6. View